Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 3/20 | 0.30 |
| ▸ | DRD1 | P21728 | 3/20 | 0.30 |
| ▸ | DRD4 | P21917 | 3/20 | 0.30 |
| ▸ | DRD5 | P21918 | 3/20 | 0.30 |
| ▸ | DRD3 | P35462 | 3/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29338337 | 0.83 | ABCB1 (0.36) | ABCB1MEN1KMT2AHRH3 | |
| SCHEMBL29338854 | 0.81 | ABCB1 (0.35) | ABCB1CHKAHRH3 | |
| SCHEMBL23422951 | 0.79 | HRH3 (0.33) | ABCB1HRH3 | |
| SCHEMBL6947992 | 0.76 | ESR2 (0.36) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL26848337 | 0.75 | DPP7 (0.39) | ABCB1MEN1KMT2A | |
| SCHEMBL14647671 | 0.75 | DPP7 (0.39) | ABCB1MEN1KMT2A | |
| SCHEMBL23747329 | 0.74 | HRH3 (0.30) | ABCB1HRH3 | |
| SCHEMBL13895125 | 0.73 | ABCB1 (0.43) | ABCB1HRH3 | |
| SCHEMBL29339100 | 0.72 | HRH3 (0.33) | ABCB1DRD2DRD1DRD4DRD5 | |
| SCHEMBL12972268 | 0.69 | HRH3 (0.36) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |